Occurrence and Implications of Chemotherapy-Induced Nausea and Vomiting (CINV)

Oncology nursing professionals play a key role in the care of patients receiving chemotherapy. However, to do so, they require access to the most recent clinical information and guidance, the latest developments in CINV therapy, and expanded knowledge of CINV pathophysiology. In addition, oncology nursing professionals need continuing education focused on appropriate screening in order to better identify patients at risk of CINV before chemotherapy begins, and developing the skills to undertak...
American Academy of CME

Immunotherapy: Harnessing the Immune System to Treat Cancer

This educational activity is directed toward oncology nurses and nurse practitioners caring for patients receiving cancer immunotherapy. Learning Objectives Upon completion of this activity, the participant will be able to: 1. List the various types of immunotherapy currently used in the management of malignancies 2. Summarize the various mechanisms of action for the different immunotherapy agents 3. Describe various toxicities for specific types of immunotherapy 4. Explain specific...
Medical Learning Institute

Patient-Centered Care of Metastatic Colon and Rectal Cancer

This educational activity is directed toward oncology nurses and nurse practitioners who have expressed a need for educational programming on the coordination of care, management of adverse events, counseling and education, and patient follow-up in metastatic colon and rectal cancer (mCRC). Such education would allow these healthcare professionals to take on leadership roles in the multi-disciplinary care of mCRC, leading to improved patient outcomes. Learning Objectives At the conclusion...
Medical Learning Institute

Hematology/Oncology PICU Issues: Case Studies

Learning Objectives: Review the importance of hemoglobin, coagulation, bone marrow, fibrinolytic and transfusion issues with the critically ill child. Describe the diagnostic laboratory data necessary to care for the child with anemia, platelet disorders, and oncologic emergencies. Prioritize the care for the child with an oncologic emergency.
Contemporary Forums

Melanoma: Updates from Brisbane, Australia The latest data in melanoma reported at the joint meeting of the 9th World Congress of Melanoma and 14th International Congress of the Society for Melanoma

Roxana S. Dronca, MD, and Lisa A. Kottschade, APRN, MSN, CNP, offer their expert insights into recent data on advanced melanoma presented at a joint meeting of the 9th World Congress of Melanoma and 14th International Congress of the Society for Melanoma Research. Listen to what these experts have to say about combination therapy in the adjuvant setting for metastatic melanoma, real-world utilization of checkpoint inhibitor therapy, sequencing options for BRAF +/- MEK Inhibition following immu...
Annenberg Center for Health Sciences at Eisenhower

Immune Checkpoint Inhibitors for Advanced Bladder Cancer: Applying Clinical Advances and Elucidating Best Practices

Advances in immunology and the advent of immune checkpoint blockade inhibition for advanced bladder cancer are poised to cause a paradigm shift in the near future. Therefore, it is of utmost importance that oncologists who treat patients with bladder cancer are ready and able to incorporate these agents into practice. In this CME activity, leading oncologists will discuss the latest treatment strategies, clinical advances, and targeted therapies for the treatment of advanced bladder cancer.
Slack Inc.

What's Hot in Melanoma? Highlights from the HemONC Today Melanoma and Cutaneous Malignancies 2017 Meeting

The development and integration of targeted therapies, as well as immunotherapies, into clinical strategies for the management of advanced melanoma has revolutionized the current treatment paradigm. Ongoing research continues to define optimal strategies for the utilization of these therapies; patients who will be provided best benefit; and emerging novel therapies with the potential to further enhance clinical outcomes. This CME activity, recorded at the 2017 HemOnc Today Melanoma and Cutaneo...
Slack Inc.

Oncology Outlook 2018: Controversies in Women's Cancers

Oncology Outlook 2018: Controversies in Women's Cancers
University of South Alabama Office of Continuing Medical Education

The Oncologist:Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm

Learning Objectives: 1. Identify paraneoplastic hyperammonemic encephalopathy associated with fibrolamellar hepatocellular carcinoma. 2. Recognize cancer associated hyperammonemic encephalopathy and describe its pathophysiology. 3. Describe treatment algorithm of cancer-associated hyperammonemic encephalopathy. We report a case of a 31-year-old man with metastatic fibrolamellar hepatocellular carcinoma (FLHCC) treated with gemcitabine and oxaliplatin complicated by hyperammonemic encepha...
Society For Translational Oncology

2nd Annual Therapeutic Advances for Advanced Practice Providers and Nurses: Hematology/Oncology Updates 2018

This course gives treatment updates in hematology and oncology with a focus on the needs of PAs, ARNPs and hematology/oncology nurses. There will be a unique opportunity for discussion with world-renowned cancer specialists.
Mayo Clinic

1st Surgical Oncology Advanced Practitioner Conference
MD Anderson

28th Annual Advances in Urology

The 28th Annual Advances in Urology meeting is designed for practicing urologists who are interested in updating their knowledge in the diagnosis, evaluation and management of urologic problems. A distinguished faculty will present advances in the management of urological problems including uro-oncology, sexual function, laparoendoscopic, robotic, minimally invasive surgery, prostate and bladder cancer and reconstruction surgery with a strong emphasis on the technical aspects of various urolo...
USF Health Professions Conferencing Corporation

Newest Oncology Agents: PD-1 Inhibitors - Clinical Information and Patient Management

This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). Most CSPE activities include the pathophysiology and clinical therapeutics of various disease states in which specialty pharmacy products and services are provided. CSPE also covers legal, regulatory and operational topics relevant to specialty pharmacy practice. Oncology agents continue to dominate new product de...

Rad Onc 2018: Updates in Radiation Oncology at MD Anderson Cancer Center
MD Anderson

The Oncologist:Ventricular-Arterial Coupling in Breast Cancer Patients Following Treatment with Anthracycline-Containing Adjuvant Chemotherapy

Learning Objectives: 1. Discuss the long-term effects of anthracycline-containing chemotherapy on the heart and vasculature and their integrative function in breast cancer survivors. 2. Cite the benefits of utilizing a stress-stimulus (i.e. exercise) to unveil subclinical cardiovascular dysfunction following anthracycline-containing chemotherapy in breast cancer. Background. Anthracycline-containing chemotherapy (Anth-C) is associated with long-term cardiovascular mortality. Although car...
Society For Translational Oncology

The Oncologist: Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents

Learning Objectives: 1. Cite the risk factors for SRE development, in order to better judge which patients would benefit most from BMA treatment. 2, Analyze the risk factors for developing multiple SREs over a long period of time in order to determine the optimal duration of BMA administration and its scheduling. Background. Bone-modifying agents (BMAs) reduce the incidence of skeletal-related events (SREs) and are thus recommended for breast cancer patients with bone metastases. However...
Society For Translational Oncology

Immune Checkpoint Inhibitors for Advanced Melanoma: Clinical Updates and Multidisciplinary Strategies

Incidence rates of melanoma in the United States continue to rise, with an estimated 87,110 new cases being diagnosed in 2017. The early detection of melanoma is imperative for optimal clinical outcomes, with 98% of early diagnosed patients in the United States surviving past 5 years. For patients who are diagnosed with melanoma that has reached the lymph nodes or has metastasized to distant organs, the 5-year survival rates drop drastically to 62% and 18%, respectively. The recent approval by...
Slack Inc.

FREE Oncology CME

Improve your treatment of cancer patients and earn FREE Oncology CME credits with these Free Oncology CME programs from Most programs are 1-2 hours long and feature slide-video lectures from specialists in Oncology.

Topics in Primary Care, Hospice, Palliative Care, Impaired Healthcare Professionals, Hematology, Oncology and the History of Medicine Western Mediterranean Cruise

Topics: ◦Osteoporosis ◦Be comfortable screening, diagnosing and treating Osteoporosis with the medications available. ◦Dementia ◦Be familiar with the work up and treatment and how to distinguish the various causes of Dementia ◦Choosing Wisely ◦Become familiar with the judicious ordering of tests and procedures ◦Case Studies in Primary Care ◦Participate in an interactive session to try and diagnose some common diseases with atypical presentations. ...
Continuing Education, Inc

Breast Cancer Management 2018

This program will review controversies in breast cancer screening and highlight new imaging modalities. Emphasis will also be placed on issues related to the management of breast cancer from its early to late stages, and methods for minimizing breast surgery. Other highlighted areas will be the latest advances in both oncologic and reconstructive breast surgery, the latest chemotherapy regimens, precision medicine advances as they apply to targeted breast therapy, and personalized breast cance...
Columbia University Medical Center

Expert Answers to Clinician Questions About Biosimilars

Questions covered include these topic areas: PRACTICAL CONSIDERATIONS Switching Substitution Education Tips FUNDAMENTALS Need for Biosimilars Biosimilars vs Generics Naming of Biosimilars EFFICACY AND APPROVAL Efficacy: Biosimilars vs Reference Biologic Extrapolation SAFETY Safety of Filgrastim-sndz Safety of Infliximab-abda Safety of Infliximab-dyyb Safety of Etanercept-szzs Safety of Adalimumab-atto
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

The Oncologist: US Food and Drug Administration Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1

Learning Objectives: 1. Describe variables associated with pembrolizumab antitumor activity in patients with metastatic non-small cell lung cancer 2. Review outcomes for patients with metastatic non-small cell lung cancer treated with pembrolizumab Outline potential adverse events associated with pembrolizumab treatment On October 2, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval for pembrolizumab, a breakthrough therapy-designated drug, for the treatment ...
Society For Translational Oncology

The Oncologist: The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study

Learning Objectives: 1. Compare access to adjuvant chemotherapy in patients with stage II colorectal cancer and mismatch repair-deficient tumors with stage-matched patients with mismatch repair-proficient tumors. 2. Discuss the effect of patient age on treatment decisions in patients with stage II colorectal cancer. 3. Discuss the influence of tumor location and T stage on the decision to offer adjuvant chemotherapy to patients with stage II colorectal cancer. Background. Testing for mi...
Society For Translational Oncology

The Oncologist: FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

Learning Objectives: 1. Discuss evaluation of patients with non-squamous NSCLC for ALK and EGFR gene alterations and initial treatment for those with ALK- or EGFR-positive NSCLC. 2. Describe a treatment plan for non-squamous NSCLC patients without actionable mutations at first and after disease progression. On October 9, 2015, the U.S. Food and Drug Administration expanded the nivolumab metastatic non-small cell lung cancer (NSCLC) indication to include patients with nonsquamous NSCLC aft...
Society For Translational Oncology

The Oncologist: Best Practices in Chronic Myeloid Leukemia Monitoring and Management

Learning Objectives: 1. Discuss the definition of key MR milestones by BCR-ABL1 transcript levels and the clinical meaning of each milestone. 2. Discuss the correct timing of MR assessment, how are MR results generated, and which variables may influence and in some cases compromise the reliability and clinical value of such results. 3. Incorporate MR and BCR-ABL1 mutation results into clinical decision algorithms. Optimal use of current therapeutic opportunities for chronic myeloid leuke...
Society For Translational Oncology

Multiple Myeloma Patient Management: Embracing New Advancements, Overcoming New Challenges

The multiple myeloma clinical landscape has evolved significantly, with not only 10 new drugs but also new staging standards (ie, the R-ISS), imaging techniques, and maintenance therapy options added in the last 12 years. To help hematologist-oncologists keep pace with these advancements and to illustrate their optimal use in practice, this Virtual Practice reviews two multiple myeloma patient cases and invites learners to help determine the best strategies for their care. Also featured is the...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

22nd Annual Update & Intensive Board Review of Internal Medicine 2016

Description & Objectives This course is designed to provide a comprehensive review of the most important advances that have recently been made in internal medicine, and to help candidates prepare for the Internal Medicine Boards or the Recertification Examination. Each of the major subspecialties will be covered including cardiology, endocrinology, gastroenterology, hematology, infectious disease, nephrology, neurology, oncology, pulmonary disease, and rheumatology. Much of the material will ...
Columbia University, Department of Medicine

The Oncologist: The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer

Learning Objectives: 1. Assess the feasibility of direct prostate biopsy for PrCa in a population at high risk of PrCa due to their family history 2. Assess the role of the currently known SNPs associated to PrCa risk in assessing the risk of the disease in a population of men with high risk of the disease 3. Compare the predictive value of the genetic score with that of PSA and RM in this high risk population Background. A better assessment of individualized prostate cancer (PrCa) risk...
Society For Translational Oncology

The Oncologist: Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systemic Review and Two-step Meta-analysis

Learning Objective: 1. Compare the use of GC and MVAC regimens for bladder cancer in the neoadjuvant setting. Background. Platinum-based neoadjuvant chemotherapy has been shown to improve survival outcomes in muscle-invasive bladder cancer patients. We performed a systematic review and meta-analysis to provide updated results of previous findings. We also summarized published data to compare clinical outcomes of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) versus gemcitabi...
Society For Translational Oncology

The Oncologist: Breast Cancer in Sub-Saharan Africa: Challenges and Opportunities to Reduce Mortality

Learning Objectives: 1. Cite the existing evidence regarding incidence of and mortality from breast cancer in low- and middle-income countries (LMIC) and the limitations of that evidence 2, Explain the inequities in breast cancer outcomes in LMIC compared with high-income countries and the reasons for these inequities 3. Discuss the existing evidence about optimal treatment and early detection strategies for breast cancer in LMIC and the gaps in the evidence base The objective of this re...
Society For Translational Oncology

The Oncologist: Advanced Ovarian Cancer: 5 Categories of Patients in View of the Results of Randomized Trials & Tumor Biology: Primary Debulking Surgery & Interval Debulking Surgery

Learning Objectives: 1. Discuss the results of randomized trials concerning debulking surgery in advanced ovarian cancer. 2. Cite the five clinical categories of stage III ovarian cancer that can correctly facilitate making decisions on timing of debulking surgery in order to avoid suboptimal surgical management Background. Standard treatment of stage III and IV advanced ovarian cancer (AOC) consists of primary debulking surgery (PDS) followed by chemotherapy. Since the publication of th...
Society For Translational Oncology

The Oncologist: A Comprehensive Look at Polypharmacy and Medication Screening Tools for the Older Cancer Patient

Learning Objectives: 1. Compare and contrast the available geriatric medication screening tools that can be applied to older patients with cancer. 2. Develop an evidence-based deprescribing process with existing medication screening tools for older patients with cancer. Inappropriate medication use and polypharmacy are extremely common among older adults. Numerous studies have discussed the importance of a comprehensive medication assessment in the general geriatric population. However, o...
Society For Translational Oncology

Critical Care of Patients With Cancer

After reading the article “Critical Care of Patients with Cancer,” the learner should be able to: 1. Describe the evolution of critical care for cancer patients. 2. Relate key principles of intensive care for critically ill cancer patients. 3. Discuss the referral and management of critically ill cancer patients in the ICU. 4. Define the long term impact of intensive care treatment on cancer patients, their relatives and caregivers.
American Cancer Society

Live CE/CME Conference aboard Alaska Cruise

Day 1: Pharmacogenomics : Guided therapy in Psychiatry, Cardiology and Oncology (5 hrs) Day 2: Transcranial Magnetic Stimulation-A novel FDA approved non invasive and non pharmacological treatment for Major Depressive Disorder (2.5 hrs) Day 3: Designer Drugs and Opioids: Identification of Patients who present with manifestation, screening tools, and management. (2.5 hrs) Day 4:Pediatric Autism Spectrum: An Overview (2 hrs) Drug Shortages and its Impact on Patient Safety and Medica...
University Learning Systems

The Oncologist: Cancer Incidence in First and Second Degree Relatives of BRCA1 and BRCA2 Mutation Carriers

Learning Objectives: 1. Discuss known risks of cancers in BRCA1 and BRCA2 mutation carriers. 2. Cite data from a single institution regarding other cancers described in families of known BRCA mutation carriers. Background. Mutations in the BRCA1 and BRCA2 genes are associated with increased risk of breast, ovarian, and several other cancers. The purpose of the present study was to evaluate the incidence of cancer in first- and second-degree relatives of BRCA mutation carriers compared wi...
Society For Translational Oncology

The Oncologist: Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature

Learning Objectives: 1. Describe the use of everolimus in clinical practice. 2. Discuss the possibility of using everolimus in neuroendocrine tumors other than pancreatic. 3. Recount the safety profile of everolimus. Background. Everolimus, an oral mTOR (mammalian target of rapamycin) inhibitor, is currently approved for the treatment of progressive pancreatic neuroendocrine tumors (NETs). Although promising, only scattered data, often from nondedicated studies, are available for extrap...
Society For Translational Oncology

Contemporary Management of von Willebrand Disease in Women: Identifying Bleeding Disorders and Preventing Hemorrhage

According to the National Hemophilia Foundation, underdiagnosis of bleeding disorders in women is a significant problem. Menorrhagia associated with bleeding disorders such as von Willebrand disease (VWD) is an overlooked, undertreated, and potentially serious condition that often has a profound impact on the affected individual’s quality of life. For women with VWD, menorrhagia is almost inevitable, with prevalence ranging from 32% to as high as 100%. Lack of awareness of the high prevalenc...

Expert Update: What's New in Essential Thrombocythemia

Appropriate early diagnosis and initiation of therapy is essential in the management of myeloproliferative neoplasms (MPNs) to enhance clinical outcomes and patient quality of life. Recent revisions in the classification of myeloid neoplasms and acute leukemia by the World Health Organization have further defined criteria for the differential diagnosis of MPNs, including criteria for the discernment of essential thrombocythemia (ET) and prefibrotic/early primary myelofibrosis. However, many ch...
Slack Inc.

The Oncologist: Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer

Learning Objectives: 1. Explain the differences between right- and left-sided colorectal cancer in terms of clinical and molecular characteristics. 2. Describe the response of RAS and BRAF wild-type right-sided colorectal cancer to anti-EGFRs. Introduction. Right- and left-sided colorectal cancers (CRCs) differ in clinical and molecular characteristics. Some retrospective analyses suggested that patients with right-sided tumors derive less benefit from anti-epidermal growth factor recept...
Society For Translational Oncology

The Oncologist: Bleomycin-Induced Pulmonary Changes on Restaging Computed Tomography Scans in Two Thirds of Testicular Cancer Patients Show No Correlation With Fibrosis Markers

Learning Objectives: 1. Discuss the bleomycin-induced pulmonary (BIP) changes that occur on restaging CT scans after treatment with bleomycin-containing chemotherapy in testicular cancer patients. 2. Discuss the use of an upfront or early biomarker to identify patients likely to develop BIP. Background. In metastatic testicular cancer patients treated with bleomycin, etoposide, and cisplatin (BEP) chemotherapy, bleomycin-induced pneumonitis is a well-known and potentially fatal side effe...
Society For Translational Oncology

The Oncologist: A Randomized Controlled Trial of a Nurse-Led Supportive Care Package (SurvivorCare) for Survivors of Colorectal Cancer

Learning Objectives: 1. Discuss the range of issues that survivors of colorectal cancer may experience. 2. Critically review interventions and models of care that aim to better meet the needs of survivors. 3. Critically review endpoints for studies that aim to improve the wellbeing of survivors and recognize challenges with study endpoints. Introduction. Colorectal cancer (CRC) and its treatments can cause distressing sequelae. We conducted a multicenter randomized controlled trial aimi...
Society For Translational Oncology

The Oncologist: Sarcomas Associated With Genetic Cancer Predisposition Syndromes: A Review

Learning Objectives: 1. Discuss the heritable cancer predisposition syndromes associated with specific sarcomas. 2. Explain the broad therapeutic principles of major sarcomas. 3. Describe the influence of genetic cancer predisposition on treatment of sarcoma and broader clinical management of the patient. Sarcomas are rare mesenchymal malignancies that demonstrate great clinical and biological heterogeneity. A variety of sarcomas develop in the context of well-defined heritable cancer pr...
Society For Translational Oncology

An Overview of Biosimilars: Potential Implications for Pharmacists

This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). Most CSPE activities include the pathophysiology and clinical therapeutics of various disease states in which specialty pharmacy products and services are provided. CSPE also covers legal, regulatory and operational topics relevant to specialty pharmacy practice. Learning Objectives The target audience for this a...

Communication for Healthcare Providers and Oncology Care Coninuum for PCP's Western Caribbean Cruise

The purpose is to provide an update on the oncology care continuum and new strategies for communication, teamwork and work-life balance for practitioners. Caring for the Caregiver- Work-life Balance ◦Using a self-awareness worksheet- including professional goals, values and priorities- identify concerns and steps to strengthen and sustain worklife balance. Decisions ◦Select appropriate directive, consultative, democratic and consensus approaches to decisions in order to achieve desir...
Continuing Education, Inc

Scale, Bail, or Fail – The CDK4/6 Inhibition Edition

Preclinical and clinical findings suggest that CDK4/6 inhibition may confer therapeutic benefits in numerous tumor types and improve outcomes in patients with mantle cell lymphoma, liposarcoma, melanoma, and non–small cell lung cancer. Additionally, studies of CDK4/6 inhibition of cancers of the prostate, lung, skin, and central nervous system are currently under way. In the format of an entertaining (but challenging!) interactive game, this edition of Scale, Bail or Fail presents and dis...
University of Cincinnati and RedMedEd

Lung Cancer Screening

LEARNING OBJECTIVES Upon completion of the activity, participants should be able to: •Review historical RCTs of lung cancer screening •Explore the purpose and utility of the ACR Lung-RADS™ •Identify individuals who may benefit from lung cancer screening
The France Foundation

Staging and Diagnosis of Lung Cancer

Upon completion of the activity, participants should be able to: •Discuss the role of imaging in lung cancer diagnosis and staging •Review descriptors identified in the 8th Edition of TNM Staging for Lung Cancer •Review methods for tissue acquisition for lung cancer diagnosis and mediastinal staging
The France Foundation

Image-Guided Thermal Ablation of Lung Cancer

Upon completion of the activity, participants should be able to: •Explore recognized standards of care for thermal ablation of NSCLC as reflected in relevant treatment guidance, with special attention to imaging-related concerns and combination of IO and conventional treatment •Review clinical trial data describing efficacy and safety of ablative therapies
The France Foundation

Lung Cancer Pathology: From Atypical Adenomatous Hyperplasia to Adenocarcinoma

Upon completion of the activity, participants should be able to: •Explore lung adenocarcinoma classification, with a focus on the transition from pre-invasive to invasive adenocarcinoma •Examine how imaging and molecular testing inform histologic findings in lung adenocarcinoma classification and comprehension of the transition from pre-invasive to invasive disease •Describe data supporting this carcinoma progression paradigm
The France Foundation

Lung Cancer: Standard of Care Treatment Algorithms (Chemotherapy/Immunotherapy)

Upon completion of the activity, participants should be able to: •Review the current treatment algorithms for lung cancer •Identify appropriate roles for systemic therapy in various stages of lung cancer •Explain tumor-specific factors that influence selection of systemic treatment modalities
The France Foundation

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.